Check out our newest treatment guideline on the use of low-dose tamoxifen in patients with estrogen receptor-positive (ER+) ductal carcinoma in situ #DCIS #BOCGuideline #CancerGuideline
#DuctalCarcinomaInSitu Brittany Bychkovsky, MD Tari King MD Dr. E Mittendorf
👇👇
physicianresources.dana-farber.org/flexpaper/trea…

USPSTF finally catches up to most other US organizations in recommending mammograms starting at age 40 but opts for biennial screening even knowing that that decreases regular imaging compared to annual recommendations. American Cancer Society favors annual and starting in 40s.

AZ reports DESTINYbreast06 trial which is first line study of TDXD vs chemo in her2 low or ultra low (i.e. 0) tumors. So essentially drug works irrespective of Her2 status and “HER2 low” is a thing of the past astrazeneca.com/media-centre/p…

Such an important question addressed in the Alliance A011502 study looking at adjuvant aspirin in breast cancer found no benefit.

Wonderful work by Wendy Chen and the Alliance team!

Dana-Farber’s Breast Oncology Center

very happy to be there with friends and colleagues! join us 👇👇👇

TP53-associated early breast cancer

227 pts, mFU: 70 mo

mAge➡️37
HR+/HER2-➡️40.9%
HR+/HER2+➡️34.4%

5y RFS (HR+/HER2)➡️61.1%!!
5y radiation-induced sarcoma➡️4.8%‼️

Quite an informative analysis. Congrats to all the researchers

OncoAlert JNCI
academic.oup.com/jnci/article-a…

What happens when #hereditarycancer testing identifies two pathogenic variants? We compared cancer risk in >600 individuals with double PVs to those with a single PV in this publication with Dana-Farber. hubs.ly/Q02qphlm0 #genechat #genechat pubs @nbagaglu Brittany Bychkovsky, MD

Worldwide, the burden of cancer falls on Low- and Middle- Income Countries. That is why DFCI CGCM is committed to a #GlobalCancerMoonshot , driving progress through sharing knowledge, expertise, compassion, and accompaniment. #WorldCancerDay

Systematic literature review by Kimia Sorouri, MD, MPH Brittany Bychkovsky, MD et al. highlighting that BRCA1/2 carriers face ⬆️ endometrial cancer risk; ⬆️ research needed to inform rr-hysterectomy in this population: brnw.ch/21wGms7 #gyncsm

Major outstanding question:
*Does adjuvant CDK4/6i use reduce late relapse?*

-Even after stopping abema after 2yrs, MONARCH-E curves continue to separate after 5yrs Journal of Clinical Oncology

We know late relapse is a major challenge for HR+/HER2- #breastcancer (EBCTG meta-analysis @nejm 2017)

New ⁦⁦ASCO⁩ guidelines published in ⁦Journal of Clinical Oncology⁩ now state all newly diagnosed patients with #breastcancer 65 y/o & younger should have BRCA testing (& many other updates). I think this is a very positive change! #genetictesting #brca #bcsm
ascopubs.org/doi/10.1200/JC…

🧵 The historic NYT v. OpenAI lawsuit filed this morning, as broken down by me, an IP and AI lawyer, general counsel, and longtime tech person and enthusiast.

Tl;dr - It's the best case yet alleging that generative AI is copyright infringement. Thread. 👇

In the biggest global experience so far with 4732 young #BRCA carriers, we found 1 in 5 pts conceived within 10 yrs after #breastcancer diagnosis

#Pregnancy after breast cancer in BRCA carriers was not associated with decreased DFS
Matteo Lambertini, MD PhD x.com/jama_current/s…

Excited to share 📃✅Endometrial Cancer Risk Among Germline BRCA1/2 Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps Brittany Bychkovsky, MD Kimia Sorouri, MD, MPH Filipa Lynce, MD, FASCO Ann Partridge MD, MPH Sara Tolaney judy garber #BreastCancer #BRCA #EndometrialCancer

Just out in JCO Precision Oncology, we review #EndometrialCancer risk among #BRCA PV carriers and offer clinical considerations to guide decisions around risk-reducing #hysterectomy .

Thank you to Brittany Bychkovsky, MD and the incredible team!

🔗 Free Open-Access link: ascopubs.org/doi/full/10.12…

#SABCS23 | Poster PO4-08-05 | Disparities in Genetic Testing Patterns and Positivity Among Patients with #BreastCancer in the CancerLINQ Real-World Oncology Database #DanaFarberSABCS23 Olga Kantor MD, MS, FACS judy garber Erica Mayer @tarikingmd Dr. E Mittendorf Brittany Bychkovsky, MD Anna Weiss

Our article is now available online Annals of Oncology
Prologue to #SABCS23 Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− #MBC ? Erica Mayer Sara Tolaney Nancy Lin, MD Dana-Farber’s Breast Oncology Center #bcsm sciencedirect.com/science/articl…

What genomic alterations drive HER2-low breast cancer? Do they differ in HER2-0 tumors? We analyzed data from >1000 patients receiving NGS at Dana-Farber to answer these questions. Incredibly proud to share the results, now published on Nature Communications. 🧵 nature.com/articles/s4146…